Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Key facts

Sponsor

AIDS Malignancy Consortium

Principal Investigator

Joel Palefsky, MD

AIDS Malignancy Consortium

Intervention

imiquimod(drug)

Enrollment

4446 enrolled

Eligibility

35 years · All sexes

Timeline

2014 – 2024

Study locations (25)

• UCLA CARE Clinic, Los Angeles, California, United States
• UCLA School of Nursing, Los Angeles, California, United States
• DAP Health, Palm Springs, California, United States
• University of California at San Francisco Anal Dysplasia Clinic, San Francisco, California, United States
• University of Colorado Hospital, Aurora, Colorado, United States
• Denver Public Health, Denver, Colorado, United States
• Capital Digestive Care, Washington D.C., District of Columbia, United States
• Dupont Circle Physicians Group, Washington D.C., District of Columbia, United States
• ACC Clinic, Jackson Hospital, Miami, Florida, United States
• University of Miami Miller School of Medicine - Sylvester Cancer Center, Miami, Florida, United States
• Grady Health System, Atlanta, Georgia, United States
• Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States
• University Medical Center New Orleans, New Orleans, Louisiana, United States
• CrescentCare Health, New Orleans, Louisiana, United States
• Boston Medical Center, Boston, Massachusetts, United States
• +10 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · The Emmes Company, LLC · University of Arkansas · University of California, San Francisco · University of Arizona

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Carcinoma of the anal canal

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07029152
  Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis
  Universitair Ziekenhuis Brussel
• ACTIVE NOT RECRUITINGPHASE3NCT06866574
  A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
  Xiamen University
• RECRUITINGPHASE2NCT06640283
  Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
  Instituto do Cancer do Estado de São Paulo
• RECRUITINGNANCT06792604
  Host Genome Methylation: a Screening Tool in Anal Cancer Detection
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGPHASE3NCT06207981
  Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
  Federation Francophone de Cancerologie Digestive
• RECRUITINGPHASE2NCT05661188
  Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
  Grupo Espanol Multidisciplinario del Cancer Digestivo
• RECRUITINGNCT06327568
  Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
  European Institute of Oncology
• RECRUITINGNCT05438836
  Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
  Herlev Hospital

See all trials for Carcinoma of the anal canal →